These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24656288)

  • 1. Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
    Dhaun N; Vachiery JL; Benza RL; Naeije R; Hwang LJ; Liu X; Teal S; Webb DJ
    J Heart Lung Transplant; 2014 May; 33(5):521-7. PubMed ID: 24656288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
    Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
    Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial.
    Vizza CD; Jansa P; Teal S; Dombi T; Zhou D
    BMC Cardiovasc Disord; 2017 Sep; 17(1):239. PubMed ID: 28874133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
    Valerio CJ; Handler CE; Kabunga P; Smith CJ; Denton CP; Coghlan JG
    Rheumatology (Oxford); 2010 Nov; 49(11):2147-53. PubMed ID: 20675359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
    Benza RL; Mehta S; Keogh A; Lawrence EC; Oudiz RJ; Barst RJ
    J Heart Lung Transplant; 2007 Jan; 26(1):63-9. PubMed ID: 17234519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.
    Benza RL; Barst RJ; Galie N; Frost A; Girgis RE; Highland KB; Strange C; Black CM; Badesch DB; Rubin L; Fleming TR; Naeije R
    Chest; 2008 Oct; 134(4):775-782. PubMed ID: 18625676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
    Barst RJ; Langleben D; Badesch D; Frost A; Lawrence EC; Shapiro S; Naeije R; Galie N;
    J Am Coll Cardiol; 2006 May; 47(10):2049-56. PubMed ID: 16697324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.
    Sandoval J; Torbicki A; Souza R; Ramírez A; Kurzyna M; Jardim C; Jerjes-Sánchez Díaz C; Teal SA; Hwang LJ; Pulido T;
    Pulm Pharmacol Ther; 2012 Feb; 25(1):33-9. PubMed ID: 22079088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
    Gabler NB; French B; Strom BL; Liu Z; Palevsky HI; Taichman DB; Kawut SM; Halpern SD
    Chest; 2012 Jan; 141(1):20-26. PubMed ID: 21940766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sitaxentan: in pulmonary arterial hypertension.
    Scott LJ
    Drugs; 2007; 67(5):761-70; discussion 771-2. PubMed ID: 17385944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the endothelin receptor antagonist bosentan on hemodynamics and exercise capacity in Japanese patients with mildly symptomatic pulmonary arterial hypertension.
    Hatano M; Yamada H; Fukuda K; Yoshioka K; Funauchi M; Kuwana M; Sata M; Taniguchi M; Nakanishi N; Saito T; Saji T; Sasayama S
    Heart Vessels; 2015 Nov; 30(6):798-804. PubMed ID: 25028167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study.
    Sitbon O; Badesch DB; Channick RN; Frost A; Robbins IM; Simonneau G; Tapson VF; Rubin LJ
    Chest; 2003 Jul; 124(1):247-54. PubMed ID: 12853530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.
    Berger RM; Haworth SG; Bonnet D; Dulac Y; Fraisse A; Galiè N; Ivy DD; Jaïs X; Miera O; Rosenzweig EB; Efficace M; Kusic-Pajic A; Beghetti M
    Int J Cardiol; 2016 Jan; 202():52-8. PubMed ID: 26386921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
    Cacoub P; Amoura Z; Langleben D
    Rev Med Interne; 2008 Apr; 29(4):283-9. PubMed ID: 18243424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sitaxsentan for treatment of pulmonary hypertension.
    Wittbrodt ET; Abubakar A
    Ann Pharmacother; 2007 Jan; 41(1):100-5. PubMed ID: 17164394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.